The provision of a single vaccine that can protect a population against all prevalent serogroups is the most important opportunity for companies hoping to access a large market share, says analyst
The meningococcal vaccines market is expected to grow from around $1.1bn in 2015 to $1.8bn by 2025 across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and Brazil, representing a compound annual growth rate of 5.4%, according to research and consulting firm GlobalData.
The company’s latest report, PharmaPoint: Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2025, says this growth will mainly be driven by adjustments in national immunisation schedules, as governments implement more inclusive vaccination programmes to prevent invasive meningococcal disease. It will also be propelled by the anticipated launch of a vaccine covering all serogroups currently prevalent in the eight major markets by combining two different meningococcal vaccines, thereby decreasing the dosage burden.
Mirco Junker, GlobalData’s Analyst covering Infectious Diseases, said: 'Although the meningococcal vaccine market in the eight major markets is highly mature, and the continuous decline in incidence rates of meningococcal disease across most of these countries will act as a barrier to launching new products, there will be several opportunities for a current or future player to distinguish itself from the competition.
The meningococcal vaccines market is characterised by a large diversity of vaccines
'For example, the meningococcal vaccines market is characterised by a large diversity of vaccines, with each covering only a specific serogroup or a set of serogroups. However, the epidemiology of serogroup distribution varies by country and over time. Therefore, providing a single vaccine that can protect the population against all prevalent serogroups will represent the most important opportunity to access a larger market share during the forecast period, by reducing the number of vaccines required to prevent meningococcal disease.'
Traditionally, the meningococcal vaccine marketplace has been dominated by Big Pharma, with Sanofi, GlaxoSmithKline, Pfizer and Novartis providing the majority of commercially available vaccines over the past decade.
But in the last few years, the meningococcal vaccine market has experienced additional changes, after Novartis sold its meningococcal vaccine portfolio to GSK, and after the recent launch of GSK’s Bexsero and Pfizer’s Trumenba, the first two vaccines to offer protection against serogroup B.
GlobalData expects that GSK will pass Sanofi as the main provider of meningococcal vaccines by the end of this forecast period.
This growth in GSK’s market share will be driven by Bexsero, which is expected to reach sales of more than $570m in 2025, as well as the UK firm's novel pentavalent vaccine, MenABCWY, which is expected to launch in the US and five European countries during the forecast period.